Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 November 2023 | Story Michelle Nöthling | Photo Andile Andries Ndlovu
Nelisiwe Vilakazi and Abigail Webb
Nelisiwe Vilakazi (Head of Department for Social Development: KZN) and Abigail Webb during the ASASWEI International Conference and Awards 2023.

In a remarkable feat, Abigail ‘Zinhle’ Webb has clinched the prestigious Best Student Achievement Award from the Association of South African Social Work Education Institutions (ASASWEI), standing out among the nation's top-ranking students. This accolade, beyond acknowledging academic prowess, demands a notable contribution to the community – a criterion Abigail undeniably fulfils.

Elizabeth Msadu, Assistant Director of Student Counselling and Development and Abigail’s supervisor during her final year in Social Work at the University of the Free State (UFS) commends Abigail for  “her passion, integrity, high standards, and perhaps most of all, how selflessly she strives to improve the lives of the students around her.” 

Community engagement: breaking taboos

Abigail's success is not confined to academic excellence; her proactive approach to community issues is equally commendable. Observing the free condom container in her residence bathroom one day, she questioned the absence of support for female students regarding sanitary products. She found that “there is still immense shame around vaginal health.” This led to the initiation of workshops and the #comebleedwithusperiod social media challenge, normalising discussions around women’s menstrual health.

During her tenure on Akasia’s Residence Committee and as Prime this year, Abigail identified a reluctance among female students to assume leadership roles. Questioning this disparity, she launched a project aimed at addressing female apprehension surrounding leadership and failure. Through this initiative, Abigail empowered female students to embrace leadership positions and overcome societal expectations. 

Future plans: a commitment to growth

While Abigail is drawn to child and family services, and adoption work, she plans to gain practical experience before pursuing a Master’s degree. Inspired by the researchers she encountered at the ASASWEI conference and award ceremony, she expresses her newfound interest in research, envisioning a future where she actively contributes to the field.

Time well spent: reflecting on four years

Reflecting on her proudest achievements she said, “I think I’m most proud that I spent my time well. I lived to my fullest during my four years of study.” Recognising the crucial role of belonging in student success, she emphasises the significance of forming connections. From a shy, first-year student with a stutter, Abigail evolved into a dynamic force, dedicated to connecting and serving the community. 

As Abigail approaches the end of her studies, she acknowledges the uncertainty of the next step but asserts with confidence, “It’s going to be okay. I’m going to be okay.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept